BioprocessUpdates’ Post

Last week's ISCT, International Society for Cell & Gene Therapy meeting was full to the brim with incredible panels and cutting-edge presentations. We attended as many as we could, here's what we thought were some of the highlights and most interesting discussions: 🔥 TILS promise for solid tumours is HOT right now ⏰ We need automation solutions EARLY - from R&D through to GMP. How do we reward early adopters through funding and regulatory channels? 🏥 Patient focus from regulatory pathways to rethinking what patient access could look like including ultra-rare and perpetual IND considerations 📈 Platform technologies were on full display this year, bringing us closer towards closed, automated and data-driven manufacturing  What would you add to the list? #ISCT24 #celltherapy #automation #bioreactors #patientaccess

We're committed to helping our customers better understand and manage the risks they face. The FDA recently approved Casgevy, a groundbreaking new gene therapy for the treatment of sickle cell disease with an incredible $2.2 million price tag. Cell and gene therapies like Casgevy can present a financial challenge for companies with self-funded health plans. Read more in our latest Cell and Gene Therapy State of the Market: https://ow.ly/IYvU50QVZMz If you’re a Berkley Accident and Health customer, we can offer cell and gene therapy insights and payment integrity services through our relationship with Emerging Therapy Solutions (ETS). #riskmanagement #stoploss #groupcaptives

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

In our new article, Boris Aleynik from 908 Devices explores how cell therapies could redefine disease treatment by addressing root causes rather than symptoms. Learn about key manufacturing challenges, such as scalability and standardization, and innovative solutions like automation, Process Analytical Technology, and CRISPR-based gene editing to advance personalized medicine. Read here: https://lnkd.in/gsyrPje3

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. Highlights: - Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies. - Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity. -Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies. What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications? #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

Join me in this Fast Focus to discuss the latest trends in personalized medicine and health technology assessment, based on recent views shared by Mike Drummond. In this video, I reflect on Mike's comments and the potential of gene therapy, the challenges of cost-effectiveness, and the intriguing shift in data availability for new drug approvals. He shares insights on managing uncertainty in healthcare decision-making and adapting to fast-track approval processes. #SyenzaTeam #PersonalizedMedicine #GeneTherapy, #CostEffectiveness,

What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications?

Are you ready for the next revolution in healthcare? Cell and gene therapies are poised to transform medicine as we know it. Biotech marketers and scientists face a common challenge: effectively communicating the complexities and potential of these groundbreaking therapies to stakeholders and the public. The technical nature of the field often creates barriers to understanding and engagement. Our latest blog breaks down the essentials of these innovative treatments. We explore the latest advancements, regulatory challenges, and future directions, providing you with a helpful overview of the landscape. Whether you're a marketer, scientist, or CEO, this knowledge will empower you to navigate the rapidly evolving world of cell and gene therapies with confidence. Read now: https://hubs.li/Q02KNPsG0 #BiotechMarketing #CellAndGeneTherapy #LifeScienceInnovation #Healthcare #PersonalizedMedicine

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds Hannah Kurth